|
Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases
|
|
|
|
|
|
|
|
|
Yiming Zhong, Amy J. Johnson, John C. Byrd, and Jason A. Dubovsky
|
|
The Ohio State University
|
Division of Hematology, Department of Internal Medicine, OSU, 320 W. 10th Avenue, Columbus, OH 43210, USA
|
yiming.zhong@osumc.edu
|
|
|
|
|
|
|
|
IL2-inducible T-cell kinase (ITK), a member of the Tec family tyrosine kinases, is the predominant Tec kinase in T cells and natural killer (NK) cells mediating T cell receptor (TCR) and Fc receptor (Fc R) initiated signal transduction. ITK deficiency results in impaired T and NK cell functions, leading to various disorders including malignancies, inflammation, and autoimmune diseases. In this mini-review, the role of ITK in Tcell signaling and the development of small molecule inhibitors of ITK for the treatment of T-cell related disorders is examined.
|
|
|
|
|
|
|
|